



LAO PEOPLE 'S DEMOCRATIC REPUBLIC
PEACE INDEPENDENCE DEMOCRACY UNITY PROSPERITY

MINISTRY OF HEALTH
FOOD AND DRUG DEPARTMENT
TEL (856 21) 214013, 214014
FAX: (856 21) 214015.

Certificate of Drug Registration

Registration Number:06-LM-10041-26

ALI-LENA

Dosage Form	TABLET, FILM COATED
Active Ingredients	LENACAPAVIR SODIUM 306.8 MG
Description	Beige oval tablets, box of 1 x 5 tablets/blister
Size of packaging unit	5 tablets
Indications	See Annex
Manufacturer	LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY SAYSETHA DEVELOPMENT ZONE, SAYSETHA DISTRICT, VIENTIANE CAPITAL, LAO PDR

This Certificate is issued to attest that the product described above has met the minimum standards required for drug registration undertaken by the Food and Drug Department in Lao PDR.

This certificate expires, unless previously suspended or revoked, on **31 July 2031**

Note: All boxes and packaging for importations must bear the Lao Registration No. **06-LM-10041-26**

At, Vientiane, **24 June 2026**



ນ.ພຸດທະວັນ ອິນລິຄາ



Registration Number:06-LM-10041-26

ALI-LENA

ANNEX

INDICATIONS

Lenacapavir, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations

Lenacapavir ແມ່ນຢາຕ້ານ capsid ຂອງໄວຣັສ HIV-1 ທີ່ໃຊ້ຮ່ວມກັບຢາຕ້ານໄວຣັສຊະນິດອື່ນໆ ມີຂໍ້ບັງໃຊ້ໃນການຮັກສາການຕິດເຊື້ອ HIV-1 ໃນຄົນເຈັບຜູ້ໃຫຍ່ທີ່ເຄີຍຜ່ານການປິ່ນປົວດ້ວຍຢາມາຫຼາຍແລ້ວ (heavily treatment-experienced) ແຕ່ບໍ່ໄດ້ຜິນ ແລະ ມີການດີຕ່ຳຫຼາຍຊະນິດ ຢາຕ້ານໄວຣັສທີ່ໃຊ້ໃນປະຈຸບັນບໍ່ໄດ້ຜິນເນື່ອງຈາກບັນຫາການດີຢາ, ການແພ້ຢາ ຫຼື ບັນຫາຄວາມປອດໄພໃນການໃຊ້ຢາ.